Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

563
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
563
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

1.2K
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

ESMO open·2025
Same author

Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

ESMO open·2024
Same journal

Metastasis as a breakdown of the multicellular social contract.

Cancer metastasis reviews·2026
Same journal

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

Cancer metastasis reviews·2026
Same journal

Resolving translational challenges in cancer biology through yeast experimental evolution.

Cancer metastasis reviews·2026
Same journal

Spheroids and organoids to study long noncoding RNAs in cancer: how they could replace animal models.

Cancer metastasis reviews·2026
Same journal

Strategies and successes of smoking cessation methods in head and neck cancer patients: a systematic review.

Cancer metastasis reviews·2026
Same journal

The Hippo signaling pathway in pediatric brain tumors: molecular mechanisms and therapeutic opportunities.

Cancer metastasis reviews·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.7K

Pancreatic NETs: where do we stand now?

S Faivre1, D Castellano, J Strosberg

  • 1Department Medical Oncology, Beaujon University Hospital, Clichy, France, sandrine.faivre@bjn.aphp.fr.

Cancer Metastasis Reviews
|January 24, 2014
PubMed
Summary
This summary is machine-generated.

Systemic treatment for pancreatic neuroendocrine tumors involves chemotherapy and targeted drugs like everolimus and sunitinib. Biomarkers are needed to guide the selection of the most effective therapy for individual patients.

More Related Videos

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

11.2K
Application of Simplified Stent-bridging Pancreaticogastrostomy in Open Pancreaticoduodenectomy
10:09

Application of Simplified Stent-bridging Pancreaticogastrostomy in Open Pancreaticoduodenectomy

Published on: March 17, 2026

414

Related Experiment Videos

Last Updated: May 3, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.7K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

11.2K
Application of Simplified Stent-bridging Pancreaticogastrostomy in Open Pancreaticoduodenectomy
10:09

Application of Simplified Stent-bridging Pancreaticogastrostomy in Open Pancreaticoduodenectomy

Published on: March 17, 2026

414

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pancreatic neuroendocrine tumors (PNETs) management includes chemotherapy and targeted agents.
  • Current treatment selection lacks clear patient stratification biomarkers.
  • Common chemotherapy agents include streptozocin and temozolamide, often with fluoropyrimidines.

Purpose of the Study:

  • To review current systemic management options for PNETs.
  • To evaluate the efficacy and toxicity of chemotherapy, everolimus, and sunitinib.
  • To highlight the need for predictive biomarkers in PNET treatment selection.

Main Methods:

  • Review of systemic therapies for PNETs.
  • Analysis of data regarding chemotherapy (streptozocin, temozolamide), everolimus, and sunitinib.
  • Discussion of progression-free survival (PFS), overall survival, response rates, and toxicities.

Main Results:

  • Chemotherapy (streptozocin, temozolamide) shows higher response rates, beneficial for high-grade or symptomatic tumors.
  • Everolimus improves PFS but has low response rates and limiting toxicities, without improving survival.
  • Sunitinib increases PFS with a trend towards improved survival, but data is from a smaller trial.

Conclusions:

  • Biomarkers are crucial for selecting optimal systemic therapy in PNET patients.
  • Chemotherapy may be preferred for symptomatic or high-grade PNETs.
  • Targeted agents like everolimus and sunitinib offer PFS benefits but require careful toxicity management and further biomarker research.